Grants

A University of Houston pharmaceutical scientist is developing a new drug that recycles through the colon to treat children suffering with Familial Adenomatous Polyposis, a rare genetic disorder characterized by hundreds -- if not thousands -- of colorectal polyps.

Although pancreatic cancer comprises just 3 percent of cancer cases in the United States, it is the nation's third deadliest cancer due to its aggressive nature and tendency to spread. A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer (SU2C) grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved $54 million to fund 12 new studies comparing how well different treatments work in improving care for a range of conditions that impose high burdens on patients, caregivers and the healthcare system.

Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer.

The Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and SU2C, has awarded a total of $7 million in first-round 'New Therapies Challenge' grants to seven teams to explore new pancreatic cancer treatments, each receiving up to $1 million in initial funding. After research is reviewed in 14 months, $4 million per team for clinical studies awaits the most successful projects for second round funding for clinical studies.

EMBO has selected 26 life science researchers within their first four years as group leaders to become EMBO Young Investigators. They join an active network of 102 current and 314 past Young Investigators and will receive support from EMBO during the foundation of their first independent laboratory.

The doctoral program 'CompCancer - Computational Methods in Oncology: Towards Personalized Medicine in Cancer Therapies' has received approval from the German Research Foundation (DFG). As part of this research program, a new generation of researchers will be developing computer-based tools for use in cancer research. The new Research Training Group is headed by Prof. Dr. Nils Blüthgen of Charité - Universitätsmedizin Berlin.

HOMED: 'Holistic management of emerging forest pests and diseases' adopts a multi-actor approach with the goal to develop a full panel of scientific knowledge and practical solutions for the management of emerging native and non-native PnPs threatening European forests.